Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|March 15, 2002

BioPharm International

  • BioPharm International-03-15-2002
  • Volume 15
  • Issue 3

Validation of Quantitative PCR Assays?Addressing Virus Contamination Concerns

by Archie Lovatt, Donna McMutrie, John Black, and Iain Doherty Q-One Biotech Ltd. Real-time quantitative PCR has revolutionized the detection and quantification of viral contaminants. Quantitative PCR assays can detect noncytopathic viruses that have recently become a concern in testing for biopharmaceutical safety. High versatility reproducibility, and throughput of such assays decrease the time spent in development, testing, and regulatory compliance.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 24 years ago

Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?

over 24 years ago

Guest Editorial: Warning Letters ? A Symptom?

over 24 years ago

The Importance of Freezing on Lyophilization Cycle Development

over 24 years ago

Outsourcing Outlook: Using Earned-Value Analysis for Better Project Management

over 24 years ago

Business Benefits of Computer Systems Validation

over 24 years ago

A System Developer's Approach to Validation

over 24 years ago

Additional charts for the Zeid article, "Specifications and Manufacturing Change Control"

over 24 years ago

Specifications and Manufacturing Change Control: A Prototypic System for Electronic Document Tracking and Management

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more